295 related articles for article (PubMed ID: 33601187)
1. Synthesis and preliminary evaluation of
Vaidyanathan G; Mease RC; Minn I; Choi J; Chen Y; Shallal H; Kang CM; McDougald D; Kumar V; Pomper MG; Zalutsky MR
Nucl Med Biol; 2021; 94-95():67-80. PubMed ID: 33601187
[TBL] [Abstract][Full Text] [Related]
2. (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.
Kiess AP; Minn I; Vaidyanathan G; Hobbs RF; Josefsson A; Shen C; Brummet M; Chen Y; Choi J; Koumarianou E; Baidoo K; Brechbiel MW; Mease RC; Sgouros G; Zalutsky MR; Pomper MG
J Nucl Med; 2016 Oct; 57(10):1569-1575. PubMed ID: 27230930
[TBL] [Abstract][Full Text] [Related]
3. PSMA-reactive NB7 single domain antibody fragment: A potential scaffold for developing prostate cancer theranostics.
Huynh TT; Feng Y; Meshaw R; Zhao XG; Rosenfeld L; Vaidyanathan G; Papo N; Zalutsky MR
Nucl Med Biol; 2024; 134-135():108913. PubMed ID: 38703588
[TBL] [Abstract][Full Text] [Related]
4. Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors.
Vaidyanathan G; Kang CM; McDougald D; Minn I; Brummet M; Pomper MG; Zalutsky MR
Nucl Med Biol; 2018; 62-63():18-30. PubMed ID: 29803076
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.
Hammer S; Hagemann UB; Zitzmann-Kolbe S; Larsen A; Ellingsen C; Geraudie S; Grant D; Indrevoll B; Smeets R; von Ahsen O; Kristian A; Lejeune P; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS; Mumberg D
Clin Cancer Res; 2020 Apr; 26(8):1985-1996. PubMed ID: 31831560
[TBL] [Abstract][Full Text] [Related]
6. A third generation PSMA-targeted agent [
Feng Y; Meshaw RL; Finch SW; Zheng Y; Minn I; Vaidyanathan G; Pomper MG; Zalutsky MR
Nucl Med Biol; 2024; 134-135():108916. PubMed ID: 38703587
[TBL] [Abstract][Full Text] [Related]
7. An Improved
Mease RC; Kang CM; Kumar V; Banerjee SR; Minn I; Brummet M; Gabrielson KL; Feng Y; Park A; Kiess AP; Sgouros G; Vaidyanathan G; Zalutsky MR; Pomper MG
J Nucl Med; 2022 Feb; 63(2):259-267. PubMed ID: 34088772
[TBL] [Abstract][Full Text] [Related]
8. Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Wüstemann T; Barelli P; Kim D; Williams C; Zheng X; Bi C; Hu B; Warren JD; Hage DS; DiMagno SG; Babich JW
J Nucl Med; 2017 Sep; 58(9):1442-1449. PubMed ID: 28450562
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Evaluation of
Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
13.
Duan X; Cao Z; Zhu H; Liu C; Zhang X; Zhang J; Ren Y; Liu F; Cai X; Guo X; Xi Z; Pomper MG; Yang Z; Fan Y; Yang X
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1030-1040. PubMed ID: 34453203
[TBL] [Abstract][Full Text] [Related]
14. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
Deberle LM; Benešová M; Umbricht CA; Borgna F; Büchler M; Zhernosekov K; Schibli R; Müller C
Theranostics; 2020; 10(4):1678-1693. PubMed ID: 32042329
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy.
Wang S; Blaha C; Santos R; Huynh T; Hayes TR; Beckford-Vera DR; Blecha JE; Hong AS; Fogarty M; Hope TA; Raleigh DR; Wilson DM; Evans MJ; VanBrocklin HF; Ozawa T; Flavell RR
Mol Pharm; 2019 Sep; 16(9):3831-3841. PubMed ID: 31381351
[TBL] [Abstract][Full Text] [Related]
16. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
17. Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.
Lim J; Guan B; Nham K; Hao G; Sun X; Simanek EE
Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31466360
[TBL] [Abstract][Full Text] [Related]
18. Development and Preclinical Evaluation of [
El Fakiri M; Ayada N; Müller M; Hvass L; Gamzov TH; Clausen AS; Geis NM; Steinacker N; Hansson E; Lindegren S; Aneheim E; Jensen H; Eder AC; Jensen AI; Poulie CBM; Kjaer A; Eder M; Herth MM
J Nucl Med; 2024 Apr; 65(4):593-599. PubMed ID: 38423784
[TBL] [Abstract][Full Text] [Related]
19. Targeted α-therapy using astatine (
Watabe T; Kaneda-Nakashima K; Shirakami Y; Kadonaga Y; Ooe K; Wang Y; Haba H; Toyoshima A; Cardinale J; Giesel FL; Tomiyama N; Fukase K
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):849-858. PubMed ID: 36344651
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Evaluation of
Banerjee SR; Minn I; Kumar V; Josefsson A; Lisok A; Brummet M; Chen J; Kiess AP; Baidoo K; Brayton C; Mease RC; Brechbiel M; Sgouros G; Hobbs RF; Pomper MG
J Nucl Med; 2020 Jan; 61(1):80-88. PubMed ID: 31253744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
